After the markets closed on 30 September Gritstone bio, Inc. quietly admitted that the Phase II colorectal cancer trial of its neoantigen therapy Granite had disappointed. The news, coming on top of a prior setback from the same study, hit its shares hard, and the group could have difficulty raising much-needed funds.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?